Drug Database
CO

COVID-19 vaccine (ZF2001 / Zifivax / ZF 2001)

✓ Approved

Anhui Zhifei Longcom Biopharma · Recombinant Proteins · Recombinant Proteins

What is COVID-19 vaccine?

COVID-19 vaccine is a recombinant proteins developed by Anhui Zhifei Longcom Biopharma. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesZF2001, Zifivax, ZF 2001
CompanyAnhui Zhifei Longcom Biopharma
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Anhui Zhifei Longcom Biopharma

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedBMC anesthesiology2026-10-15

Impact of ophthalmic draping on end-tidal CO₂, cerebral oximetry, and optic nerve sheath diameter in cataract surgery: an observational comparison by COVID-19 pneumonia history with randomized oxygen flow allocation.

Ozturk Kivanc K, Ersoy Karka Ozlem O, Cangur Sengul S, Demir Senoglu Gizem G et al.

Ophthalmic draping during cataract surgery creates an isolated surgical field but may lead to carbon dioxide (CO₂) accumulation beneath the drape. Elevated CO₂ can cause hypercapnia, cerebral vasodilation, and increased intracranial pressure, potentially reflected by changes in cerebral oximetry and optic nerve sheath diameter (ONSD). Patients with a history of COVID-19 pneumonia may exhibit residual pulmonary dysfunction that influences these parameters during surgery. This study aimed to investigate the effects of ophthalmic draping on end-tidal CO₂, cerebral oximetry, and ONSD in patients undergoing cataract surgery and to determine whether these effects differ between patients with and without a history of COVID-19 pneumonia. This prospective comparative study included 80 ASA I-III patients aged > 18 years with and without a history of COVID-19 pneumonia who underwent unilateral phacoemulsification under local anesthesia. Participants were divided into two main groups: those with (Group A, n = 40) and without (Group B, n = 40) a history of COVID-19 pneumonia. Within each predefined COVID-19 history stratum, patients were randomly allocated by block randomization to receive either 2 L/min (A-2, B-2) or 4 L/min (A-4, B-4) oxygen insufflation beneath the surgical drape. End-tidal CO₂ and hemodynamic parameters were continuously monitored, while cerebral oximetry parameters (rSO₂, ΔO₂Hb, ΔHHb, ΔcHb) were measured bilaterally every five minutes. ONSD was assessed ultrasonographically before and after surgery. ETCO₂ values showed no significant group-by-time differences. Postoperative ONSD values were significantly higher than preoperative values within both main groups and all oxygen-flow subgroups; however, the between-group comparisons were not statistically significant. Right frontal relative deoxyhemoglobin changes (ΔHHb-right) differed significantly between Groups A and B at the 10th minute (p = 0.003), while the other cerebral oximetry parameters demonstrated no significant group- or time-dependent differences. No patient developed hypoxia or neurological deterioration. In patients undergoing short-duration unilateral phacoemulsification under local anesthesia with supplemental oxygen at 2-4 L/min, ophthalmic draping was not associated with clinically meaningful differences in ETCO₂ or ONSD, regardless of the history of COVID-19 pneumonia. Although selected cerebral oximetry parameters showed statistically significant differences between groups, all measured respiratory, hemodynamic, and cerebral physiological variables remained within physiological limits throughout the procedure. These findings should be interpreted within the context of the specific clinical settings studied. ClinicalTrials.gov, NCT05571683. Retrospectively registered on 7 October 2022.

PMID 42875739
Read full article →
PubMedThe European journal of health economics : HEPAC : health economics in prevention and care2026-10-15

Age-specific COVID-19 case dynamics during school closure periods: Evidence from 12 european countries.

Dupré Damien D, Morgenroth Edgar E

School closures were among the most widely adopted non-pharmaceutical interventions against COVID-19, yet evidence on their association with infection dynamics remains uncertain given their substantial economic and educational costs. This observational study describes age-specific COVID-19 case dynamics during school closure periods across 12 European countries using Generalised Additive Models with zero-crossing derivative analysis and Transfer Entropy. Case dynamics were heterogeneous and non-monotonic across age groups: case counts declined early but rose again within the window among the youngest cohorts (0-4 and 5-9 years). By contrast, the 10-14 group rose steadily with no turning point, and older adolescents and young adults (15-19 and 20-24 years) rose early and then declined. Transfer Entropy analysis, with Benjamini-Hochberg correction, revealed asymmetric directional relationship between age cohorts that varied across national contexts. These patterns indicate that case trajectories during closure periods were not uniform across youth age groups, with no age group showing a sustained, uninterrupted decline. Interpreted cautiously, they raise questions about the cost-benefit balance of blanket closure policies when weighed against their documented economic, educational, and distributional costs, and motivate more targeted, age-sensitive quasi-experimental evaluation for future pandemic preparedness.

PMID 42875713
Read full article →
PubMedInternational journal for equity in health2026-10-15

Gendered forms of intergenerational solidarity in the COVID-19 pandemic: an intersectional perspective on the public renegotiation of a moral resource for future health crises in Germany.

Boser Eva Katharina EK, Dörmann Lena L, Ellerich-Groppe Niklas N

During the COVID-19 pandemic, 'intergenerational solidarity' became a prominent buzzword in public debates. At the same time, a resurge of ageist stereotypes could be observed that proved to be a constant structuring element in the public renegotiation of intergenerational solidarity. Despite a growing body of research indicating that the COVID-19 pandemic also had a significant impact on inequalities related to other social categories, such as gender, the interplay between appeals for intergenerational solidarity and other social inequalities in public debates has received limited attention. To examine how appeals to intergenerational solidarity and gender-related aspects are intertwined in times of crisis, we provide an intersectional perspective on the public renegotiation of intergenerational solidarity during the COVID-19 pandemic, using the example of the German media debate. Based on a qualitative content analysis of articles from two major German weekly newspapers, Die Zeit and Welt am Sonntag, published between March 2020 and June 2022 (n = 351), we identified two paradigmatic cases for an intersectional in-depth-analysis, focusing primarily on the categorial intersection of age and gender within the material. We can observe not only a resurge of ageism and age-related stereotypes in these media representations regarding various aspects of intergenerational solidarity, but also their entanglement with gender norms. Prevailing notions of intergenerational solidarity in the media continue to rely on gendered and age-based assumptions that shape how the moral actors, the basis, contributions, and normative goals of intergenerational solidarity are elucidated. We critically discuss these claims against the backdrop of broader intersectional feminist philosophy literature on structural social inequities and injustices. Our findings illustrate the significance of a gendered and heteronormative generational divide in appeals for intergenerational solidarity that include pertinent gender and age stereotypes. Intergenerational solidarity proves to be a moral resource in times of crisis, even though it often runs the risk of reiterating and perpetuating gendered ageism. However, approaches from intersectional feminist philosophy can help to conceptualize intergenerational solidarity as a diversity-sensitive moral resource in impending health crises in Germany and beyond.

PMID 42875791
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-10-15

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Zhang Xuan-Ji XJ, Luo Jia-Rui JR, Tian Ting-Ting TT, Shi Juan J et al.

Mycobacterium tuberculosis (Mtb) infects approximately one-quarter of the global population, of whom 5%-10% develop active tuberculosis (TB). Although Bacillus Calmette-Guérin (BCG) remains the cornerstone vaccine against severe infant TB, its efficacy in adults is limited, underscoring the need for novel TB vaccines. This study aimed to design a multi-epitope vaccine, tMEV, and validate its protective potential through bioinformatic prediction and in vivo experiments. tMEV was constructed from dominant T- and B-cell epitopes derived from Mtb ESAT-6, PE35, PPE38, and PE4 proteins, fused with an adjuvant. Its vaccine candidacy was assessed via physicochemical and solubility profiling, secondary and tertiary structure modeling, TLR-4 molecular docking, molecular dynamics simulation, and immune simulation. The tMEV coding sequence was cloned into pMV361 and transformed into BCG to generate recombinant BCG (rBCG-tMEV). Immunogenicity, antigenicity, and protective efficacy were evaluated in mouse immunization and Mtb challenge models. tMEV exhibited favorable vaccine-like properties in silico. In mice, both tMEV and rBCG-tMEV induced Mtb-specific immune responses. Compared with PBS, tMEV significantly enhanced cellular and humoral immunity with a Th2-biased profile. Relative to conventional BCG, rBCG-tMEV elicited a superior mixed Th1-Th2 response and higher antigen-specific immunity, accompanied by increased secretion of IFN-γ, IL-2, TNF-α, granzyme B, and perforin. Moreover, rBCG-tMEV markedly reduced bacterial loads in the lungs and spleens of Mtb-infected mice, conferring partial protection. These findings demonstrate that tMEV and rBCG-tMEV possess robust immunogenicity and protective potential against Mtb, representing promising novel TB vaccine candidates and providing a rationale for future vaccine development and optimization.

PMID 42876677
Read full article →
PubMedBMJ public health2026-10-15

Infant vaccination coverage trajectories and immunisation system archetypes in the WHO African region, 2019-2024: a longitudinal analysis of 47 countries.

Adamu Abdu A AA, Teka Bekele Aschalew A, Masresha Balcha Girma BG, Rey Lynda L et al.

COVID-19 disrupted childhood vaccination, but country-specific heterogeneity in diphtheria-tetanus-pertussis-containing vaccines (DTP3) coverage across the WHO African region remains poorly understood. This study addressed this gap by quantifying temporal trajectories and identifying latent structural patterns in DTP3 coverage across all 47 countries in the WHO African region from 2019 to 2024, spanning the onset and recovery phases of the COVID-19 pandemic. Country-level DTP3 coverage data from 2019 to 2024 were extracted from the WHO/United Nations Children's Fund Estimates of National Immunisation Coverage, published in July 2025. Country-specific ordinary least squares regression models estimated annual rates of change (slopes) in DTP3 coverage, while linear mixed-effects modelling decomposed within-country and between-country variance components. Principal component (PC) analysis (PCA) was then applied to the 6-year coverage matrix to derive two dominant, uncorrelated components capturing coverage level (PC1) and temporal trajectory (PC2). K-means clustering of PC scores grouped countries into empirically distinct immunisation system archetypes. Between 2019 and 2024, the estimated annual rate of change in DTP3 coverage was positive in 21 countries and negative in 24; Eritrea and Burkina Faso showed no evidence of a linear trend. The fixed-effect slope was 0.07 percentage points per year (95% CI -0.34 to 0.47; p=0.75), indicating no statistically significant net regional change, while between-country heterogeneity was substantial (random-intercept variance, 188.18; random-slope variance, 1.18). PCA showed that PC1 dominated, explaining 93% of variance (capturing sustained coverage level), with PC2 contributing an additional 3% (capturing temporal trajectory). K-means clustering of PC scores yielded four archetypes: cluster 1 (high coverage, consolidating; n=15), cluster 2 (chronically low coverage, divergent trajectories; n=9), cluster 3 (mid-low coverage, predominantly improving; n=11) and cluster 4 (mid-high coverage, erosion risk; n=12). This study generated an empirically derived, model-driven typology of immunisation system performance across the WHO African region, characterised by four distinct DTP3 coverage archetypes. The typology provides decision-makers with a granular basis for differentiating programmatic strategies, prioritising resource deployment and designing cluster-specific implementation research rather than applying uniform regional solutions.

PMID 42876748
Read full article →
PubMedFrontiers in public health2026-10-15

Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs.

Schito Marco M, Coe Stacey S, Seltzer Jaime J, Davis Hannah E HE et al.

Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.

PMID 42876939
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine